These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
252 related articles for article (PubMed ID: 33345605)
1. Clinical implications and outcomes of the ORION Phase III trials. Brandts J; Ray KK Future Cardiol; 2021 Aug; 17(5):769-777. PubMed ID: 33345605 [TBL] [Abstract][Full Text] [Related]
2. Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial. Raal F; Durst R; Bi R; Talloczy Z; Maheux P; Lesogor A; Kastelein JJP; Circulation; 2024 Jan; 149(5):354-362. PubMed ID: 37850379 [TBL] [Abstract][Full Text] [Related]
3. Inclisiran for the treatment of cardiovascular disease: the ORION clinical development program. Stoekenbroek RM; Kallend D; Wijngaard PL; Kastelein JJ Future Cardiol; 2018 Nov; 14(6):433-442. PubMed ID: 30375244 [TBL] [Abstract][Full Text] [Related]
4. An update on inclisiran for the treatment of elevated LDL cholesterol. Barkas F; Ray K Expert Opin Pharmacother; 2024 Mar; 25(4):349-358. PubMed ID: 38549399 [TBL] [Abstract][Full Text] [Related]
5. Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis. Wright RS; Ray KK; Raal FJ; Kallend DG; Jaros M; Koenig W; Leiter LA; Landmesser U; Schwartz GG; Friedman A; Wijngaard PLJ; Garcia Conde L; Kastelein JJP; J Am Coll Cardiol; 2021 Mar; 77(9):1182-1193. PubMed ID: 33663735 [TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of inclisiran in South African patients at high cardiovascular risk: A subanalysis of the ORION phase III clinical trials. Raal F; Abelson M; Blignaut S; Burgess L; Coetzer S; Ebrahim I; Gibbon A; Jansen van Rensburg D; Jaros M; Lombard L; Van Nieuwenhuizen E; Pretorius M; Van Tonder A; Urbach D S Afr Med J; 2022 May; 112(6):426-432. PubMed ID: 36217872 [TBL] [Abstract][Full Text] [Related]
7. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. Ray KK; Wright RS; Kallend D; Koenig W; Leiter LA; Raal FJ; Bisch JA; Richardson T; Jaros M; Wijngaard PLJ; Kastelein JJP; N Engl J Med; 2020 Apr; 382(16):1507-1519. PubMed ID: 32187462 [TBL] [Abstract][Full Text] [Related]
8. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial. Ray KK; Troquay RPT; Visseren FLJ; Leiter LA; Scott Wright R; Vikarunnessa S; Talloczy Z; Zang X; Maheux P; Lesogor A; Landmesser U Lancet Diabetes Endocrinol; 2023 Feb; 11(2):109-119. PubMed ID: 36620965 [TBL] [Abstract][Full Text] [Related]
9. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. Raal FJ; Kallend D; Ray KK; Turner T; Koenig W; Wright RS; Wijngaard PLJ; Curcio D; Jaros MJ; Leiter LA; Kastelein JJP; N Engl J Med; 2020 Apr; 382(16):1520-1530. PubMed ID: 32197277 [TBL] [Abstract][Full Text] [Related]
10. Rationale and design of two trials assessing the efficacy, safety, and tolerability of inclisiran in adolescents with homozygous and heterozygous familial hypercholesterolaemia. Reijman MD; Schweizer A; Peterson ALH; Bruckert E; Stratz C; Defesche JC; Hegele RA; Wiegman A Eur J Prev Cardiol; 2022 Jul; 29(9):1361-1368. PubMed ID: 35175352 [TBL] [Abstract][Full Text] [Related]
11. Inclisiran: A First-in-Class siRNA Therapy for Lowering Low-Density Lipoprotein Cholesterol. Samuel E; Watford M; Egolum UO; Ombengi DN; Ling H; Cates DW Ann Pharmacother; 2023 Mar; 57(3):317-324. PubMed ID: 35775133 [TBL] [Abstract][Full Text] [Related]